MedWatch

High growth at low margins is better than the reverse, says Novo Nordisk CEO

Novo Nordisk's growth is a sign of its products' well-being on the market, says CEO Lars Fruergaard Jørgensen. "Growth is the best indicator for future success," he tells Danish media Børsen.

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH

The strongest growth in many years, perhaps ever. This is how CEO at Novo Nordisk Lars Fruergaard Jørgensen describes his firm's current advancements in an interview with Danish business daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs